Search results for "Risedronic Acid"
showing 5 items of 5 documents
Thermodynamics of interaction between risedronic acid and metal cations: investigations in solution and in the solid state
2019
Risedronic acid (see Figure 1) belongs to the class of biphosphonates (BP), widely used in the medical field to treat bone disorders. Bisphosphonates (BPs, e.g., alendronate, risedronate, and ibandronate) help to maintain bone mass, to inhibit osteoclast-mediated bone resorption, and to reduce the risk of both vertebral and non-vertebral fractures. The clinical efficacy of BPs is mainly based on two key properties: their capacity to strongly bind hydroxyapatite crystals of bone, and their inhibitory effects on osteoclast precursors and mature osteoclasts. Interaction of risedronate with metal cations is poorly investigated. Qualitatively, it is indicated that adsorption of risedronate is in…
Risedronate complexes with Mg2+, Zn2+, Pb2+, and Cu2+: Species thermodynamics and sequestering ability in NaCl(aq) at different ionic strengths and a…
2021
Abstract In this paper, potentiometry and calorimetry were used to determine the thermodynamics of interaction between risedronate and four bivalent metal cations, namely: Mg2+, Zn2+, Pb2+, and Cu2+ in aqueous NaCl solutions at different ionic strengths and at T = 298.15 K. The data analysis allowed us to ascertain that the main species formed were the MLH2, MLH, ML and M2L; however scarcely soluble species precipitated at acidic pH values, between 4 and 7 depending on the metal cation involved, probably due to the formation of the neutral M2L(s) species. Comparison of the stability constants with other similar ligands suggests that metal complexation occurs through the phosphonate with an …
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
2022
AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
2011
The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC). In a group of 51 elderly women (aged 76.4 ± 5.0 years) considered for adjuvant aromatase inhibitors for EBC, 24 patients with T-scores ≥ -2 and no prevalent fractures received anastrozole 1 mg/day (group A), and 27 patients with T-scores < -2, or with T-scores ≥ -2 and prevalent fractures (group B), received anastrozole (1 mg/day) plus risedronate (35 mg/week). Both groups received supplementation with 1 g calcium carbonate and 800 IU vitamin D per day. Differen…
Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study
2006
None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …